Form 4: NeuroSense GM awarded 200,000 restricted shares

NeuroSense Therapeutics’ General Manager Hagit Binder reported a grant of 200,000 restricted ordinary shares at $0, vesting quarterly over two years.

Summary

• On 2026-03-26, General Manager Hagit Binder acquired 200,000 restricted ordinary shares of NeuroSense Therapeutics at $0 under the 2018 Share Incentive Plan.
• Following the grant, Binder beneficially owns 521,806 ordinary shares, held directly.
• The restricted shares vest in equal quarterly installments over a two-year period beginning 2026-03-26, contingent on continued service.
• To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued under the plan are registered in the name of a trustee.
• No derivative securities were reported.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as neutral to slightly positive: it enhances alignment and retention but is a standard, zero-cost equity grant without incremental operational information.

Positives

• Equity award aligns management incentives with shareholders via increased ownership.
• Structured vesting over two years supports executive retention through 2028.
• Post-grant beneficial ownership totals 521,806 shares, signaling a meaningful stake by a senior officer.

Negatives

• The award was granted at $0 consideration rather than purchased on the open market, offering a weaker positive signal than insider buying.
• Equity issuance under the incentive plan can contribute to shareholder dilution.

Future Outlook

No forward-looking statements or guidance are provided; this is an insider equity award disclosure.

Industry Context

StockSavvy.ai notes that time-based equity grants to executives are common in biotech to conserve cash and align incentives; such awards typically carry limited near-term signaling for fundamentals compared with open-market insider purchases.

Comparison to Industry Standards

• In U.S.-listed biotech, time-based restricted stock awards vesting quarterly over one to three years are standard retention tools for senior managers; a two-year schedule aligns with common practice.
• Open-market insider purchases generally provide a stronger positive market signal than zero-cost equity awards; by that benchmark, this transaction is neutral in signaling.
• Without disclosure of total shares outstanding or grant-date fair value, precise benchmarking of grant size versus peers (e.g., similar micro-cap biotech executive awards as a percent of float) cannot be determined from this document alone.

Related Party Transactions

• Grant of 200,000 restricted ordinary shares to officer Hagit Binder under the 2018 Share Incentive Plan at $0 consideration, vesting quarterly over two years.

Stakeholder Impact

• Shareholders: Equity compensation may modestly dilute ownership but aligns management with shareholder outcomes.
• Employees: Reinforces use of equity-based retention and incentive structures.
• Creditors: Non-cash award has no direct impact on liquidity or leverage.

Next Steps

• Shares vest in equal quarterly installments from 2026-03-26 through the two-year vesting period, subject to continued service.

Key Dates

Keywords

NeuroSense Therapeutics, NRSN, Form 4, insider ownership, restricted shares, equity grant, Hagit Binder, 2018 Share Incentive Plan, Section 102 Israeli Tax Ordinance, vesting schedule